MicroRNA jsou krátké (18-24 nukleotidů) nekódující, velmi stabilní molekuly RNA, jejichž funkce zahrnuje vše od regulace klíčových signálních drah na molekulární úrovni až po rychlou buněčnou odpověď organismu na patologické stavy. microRNA jsou stabilní v tělních tekutinách a představují velmi perspektivní diagnostický cíl pro včasnou identifikaci široké škály onemocnění. V tomto souhrnném článku je uveden přehled kandidátních diagnostických miRNA vhodných pro využití v diagnostice onkologické kardiotoxicity.
MicroRNAs are very stable short (18-24) noncoding RNAs. The function of miRNA molecules includes everything from the regulation of key signalling pathways at the molecular level to the rapid cellular response to pathological conditions. miRNAs are stable in body fluids and represent a very promising diagnostic targets for the early identification of a wide range of diseases. This summary article provides an overview of candidate diagnostic miRNAs suitable for use in the diagnosis of oncological cardiotoxicity.
miRNAs are promising biomarkers but methods for their measurement are not clear. We therefore examined three miRNA detection technologies and considered the analytical characteristics essential for clinical utilization. TaqMan assays, SplintR-qPCR and miREIA were compared for their absolute quantification bias, conformity and robustness. Absolute concentrations of miR-142-5p, miR-23a-3p and miR-93-5p were measured with all three methods using 30 samples. Robustness was evaluated by measurement of miR-21-5p in five uniform experiments. Correlations were miRNA-specific, but we observed a different absolute concentration range in RT-qPCR (fmol/μl) and methods evading the RT process (amol/μl). Consistently, RT-less methods reported better robustness (CV 8-19%) than RT-qPCR (CV 39-50%). The calibration curve in TaqMan Advanced assay was influenced by dilution media. Methods avoiding RT seem to be a promising future alternative for miRNA measurement.
BACKGROUND: Complement C1q tumor necrosis factor-related protein 1 (CTRP1), a recently identified adipokine, was found to stimulate aldosterone production. Obesity and metabolic syndrome are frequently associated with elevated levels of aldosterone. Therefore, it would be interesting to investigate whether the secretion of CTRP1 in human serum is associated with obesity as well as with hypertension. AIM: This study evaluated serum CTRP1 concentrations in healthy individuals and patients with metabolic syndrome. METHODS: Serum samples from 61 healthy individuals and 46 patients with metabolic syndrome were measured for CTRP1 by enzyme-linked immunosorbent assay (ELISA). RESULTS: Correlation analyses showed that serum CTRP1 in healthy individuals did not correlate with BMI, leptin, TG, HDL-CH, and LDL-CH; however, in patients with metabolic syndrome, CTRP1 correlated with glucose, HbA1c and BMI. CTRP1 level was significantly higher in subjects with metabolic syndrome compared to healthy subjects. DISCUSSION: Our results support the hypothesis that adipokine CTRP1 is associated with metabolic syndrome and obesity compared to healthy individuals.
- MeSH
- biologické markery krev MeSH
- dospělí MeSH
- ELISA metody MeSH
- glykovaný hemoglobin analýza MeSH
- index tělesné hmotnosti MeSH
- krevní glukóza analýza MeSH
- leptin krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- metabolický syndrom krev MeSH
- obezita krev MeSH
- pilotní projekty MeSH
- proteiny analýza imunologie MeSH
- referenční hodnoty MeSH
- senioři MeSH
- triglyceridy krev MeSH
- zkřížené reakce MeSH
- zvířata MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
